The stock of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has increased by 3.97 when compared to last closing price of 12.20. Despite this, the company has experienced a -8.90% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-21 that Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reduction and dosing frequency compared to its main competitor, Olezarsen, with a pivotal PDUFA date on November 18. ARWR’s strong financial position is bolstered by a recent deal with Sarepta, extending its cash runway into 2028.
Is It Worth Investing in Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Right Now?
The 36-month beta value for ARWR is also noteworthy at 0.92. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for ARWR is 114.16M, and at present, short sellers hold a 9.15% of that float. The average trading volume of ARWR on April 03, 2025 was 1.92M shares.
ARWR’s Market Performance
ARWR stock saw a decrease of -8.90% in the past week, with a monthly decline of -25.83% and a quarterly a decrease of -31.81%. The volatility ratio for the week is 5.96%, and the volatility levels for the last 30 days are 6.08% for Arrowhead Pharmaceuticals Inc (ARWR). The simple moving average for the past 20 days is -14.43% for ARWR’s stock, with a -40.31% simple moving average for the past 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Goldman repeating the rating for ARWR by listing it as a “Neutral.” The predicted price for ARWR in the upcoming period, according to Goldman is $31 based on the research report published on June 05, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $29. The rating they have provided for ARWR stocks is “Buy” according to the report published on December 04th, 2023.
Citigroup gave a rating of “Neutral” to ARWR, setting the target price at $33 in the report published on September 19th of the previous year.
ARWR Trading at -28.29% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.27% of loss for the given period.
Volatility was left at 6.08%, however, over the last 30 days, the volatility rate increased by 5.96%, as shares sank -26.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.78% lower at present.
During the last 5 trading sessions, ARWR fell by -8.90%, which changed the moving average for the period of 200-days by -52.11% in comparison to the 20-day moving average, which settled at $14.83. In addition, Arrowhead Pharmaceuticals Inc saw -32.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from Anzalone Christopher Richard, who sale 51,425 shares at the price of $15.07 back on Mar 13 ’25. After this action, Anzalone Christopher Richard now owns 4,062,377 shares of Arrowhead Pharmaceuticals Inc, valued at $774,975 using the latest closing price.
Anzalone Christopher Richard, the Officer of Arrowhead Pharmaceuticals Inc, proposed sale 51,425 shares at $15.07 during a trade that took place back on Mar 13 ’25, which means that Anzalone Christopher Richard is holding shares at $774,785 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -250.38 for the present operating margin
- -2.72 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc stands at -255.89. The total capital return value is set at -0.68. Equity return is now at value -600.68, with -78.01 for asset returns.
Based on Arrowhead Pharmaceuticals Inc (ARWR), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -4.24. The debt to equity ratio resting at 2.2. The interest coverage ratio of the stock is -12.87.
Currently, EBITDA for the company is -561.51 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 721.81. The receivables turnover for the company is 1.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.09.
Conclusion
In summary, Arrowhead Pharmaceuticals Inc (ARWR) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
